|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100052935 |
|
最近更新日期: Date of Last Refreshed on: |
2021-11-06 17:39:27 |
|
注册时间: Date of Registration: |
2021-11-06 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
消化道黏膜保护胶临床应用的有效性和安全性研究 |
|
Public title: |
Efficacy and safety of digestive tract mucosal protective adhesive in clinical application |
|
注册题目简写: |
胃粘膜保护胶的有效性和安全性 |
|
English Acronym: |
Efficacy and safety of gastric mucosal protective adhesive |
|
研究课题的正式科学名称: |
消化道黏膜保护胶临床应用的有效性和安全性研究 |
|
Scientific title: |
Efficacy and safety of digestive tract mucosal protective adhesive in clinical application |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
2020-Q-004-01 |
|
申请注册联系人: |
金小亮 |
研究负责人: |
吕宾 |
|
Applicant: |
Xiaoliang Jin |
Study leader: |
Bin Lyu |
|
申请注册联系人电话: Applicant telephone: |
15757303532 |
研究负责人电话: Study leader's telephone: |
13906515409 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jin_xiaoliang@foxmail.com |
研究负责人电子邮件: Study leader's E-mail: |
lvbin@medmail.com.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
浙江省杭州市邮电路54号 |
研究负责人通讯地址: |
浙江省杭州市邮电路54号 |
|
Applicant address: |
Youdian Road 54, Hangzhou, Zhejiang Province |
Study leader's address: |
Youdian Road 54, Hangzhou, Zhejiang Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江中医药大学附属第一医院 |
||
|
Applicant's institution: |
First Affiliated Hospital of Zhejiang Chinese Medical University |
||
|
研究负责人所在单位: |
浙江中医药大学附属第一医院 |
||
|
Affiliation of the Leader: |
First Affiliated Hospital of Zhejiang Chinese Medical Universty |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2020-Q-004-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江中医药大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medicine University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-12-25 00:00:00 |
||
|
伦理委员会联系人: |
夏冰 |
||
|
Contact Name of the ethic committee: |
Bing Xia |
||
|
伦理委员会联系地址: |
浙江省杭州市上城区邮电路23号长城资产大厦320伦理办公室 |
||
|
Contact Address of the ethic committee: |
Office 320, Great Wall Asset Building, Youdian Road 23, Shangcheng District, Hangzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
0571-87072953 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
zjhtcmirb@163.com |
|
研究实施负责(组长)单位: |
浙江中医药大学附属第一医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
First Affiliated Hospital of Zhejiang Chinese Medical University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省杭州市邮电路54号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
Youdian Road 54, Hangzhou, Zhejiang Province |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
杭州英健生物科技有限公司 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Hangzhou Yingjian Biological Technology Co., LTD |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Gastric ulcer after ESD surgery |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
治疗新技术临床试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
New Treatment Measure Clinical Study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究的目的是评估杭州英健生物科技有限公司的“消化道黏膜保护胶”临床应用的有效性和安全性。采用目前临床上ESD术后未处理的裸露创面作为对照。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to evaluate the efficacy and safety of digestive tract mucosal protective glue in clinical application of Hangzhou Yingjian Biotechnology Co., Ltd. At present, the untreated exposed ulcers after ESD were used as the control group. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1)受试者年龄在18-75岁,性别不限;2)诊断为早期胃癌和胃良性肿瘤并符合ESD手术指征(创面直径大于2cm);3)自愿签署知情同意书; |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1) subjects aged from 18 to 75 years old, regardless of gender; 2) diagnosed as early gastric cancer and gastric benign tumor and in accordance with ESD surgical indications (wound diameter is larger than 2cm); 3) sign informed consent form voluntarily |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1)伴有活动性感染或有严重系统性疾病的患者;2)严重肝功能或心肺功能损害;3)有凝血或出血功能障碍者;4)怀孕或哺乳期患者;5)6周内接受过糖皮质激素治疗者(不包括吸入剂和滴眼剂);6)1周内使用过可能影响血凝系统的药物:如血小板受体拮抗剂阿昔单抗,替罗非班;氯吡格雷;其它抗凝药物或促凝药物;7)已知对海藻多糖和多聚赖氨酸过敏患者;8)医生认为不适合该产品手术的患者。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1) patients with active infection or severe systemic diseases; 2) severe impairment of liver function or cardiopulmonary function; 3) patients with coagulation or bleeding dysfunction; 4) pregnant or lactating patients; 5) those who have received glucocorticoid treatment within 6 weeks (excluding inhalers and eye drops); 6) use of drugs that may affect the blood coagulation system within 1 week: such as platelet receptor antagonist abciximab, tirofiban. Clopidogrel; other anticoagulants or procoagulants; 7) patients known to be allergic to seaweed polysaccharides and polylysine; 8) patients who are not considered suitable for surgery with this product. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2020-08-01 00:00:00至 To 2021-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2020-09-01 00:00:00 至 To 2021-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
浙江中医药大学附属第一医院信息部临床评价中心人员 随机序列产生采用SAS 9.3 软件进行随机分组,代码如下: data hhh; input strata; do hosp=1 to strata; input n b; do i=1 to n/b; do j=1 to b; r=uniform(20200908); output;end;end;end; cards; 3 40 4 40 4 40 4 ;run; data iii;set hhh; number=_n_; proc rank out=jjj; ranks r_rank;var r; by hosp i; data kkk;set |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Staff member, Clinical Evaluation Center, Information Department, The First Affiliated Hospital of Zhejiang Chinese Medicine University SAS 9.3 software is used for random grouping for random sequence generation, and the code is as follows: data hhh; input strata; do hosp=1 to strata; input n b; do i=1 to |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
未公开 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
undisclose |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
纸质CRF表和电子采集及管理系统EDC共同储存,EDC网址:http://60.191.20.66/wy_wnm |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Paper CRF forms are stored together with electronic collection and management system EDC (website: http://60.191.20.66/wy_wnm) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |